VCs Keep Capital Flowing To Stent Start-Ups
This article was originally published in Start Up
Venture capital investments in stent companies have remained strong over the past three years. According to Windhover's Strategic Transactions Database, VCs invested more than $114 in stent start-ups last year, compared with $31 million in 2006 and $70 million in 2007.
You may also be interested in...
Minvasys: Tailoring the Stent to Fit the Lesion in Bifurcations
Bifurcated lesions remain one of the most challenging unmet clinical needs facing interventional cardiologists, even with current drug-eluting stents. Here's how one small company is challenging bigger players in this promising market by developing polymer-free DES designed specifically for these difficult bifurcated lesions.
Xtent and the Next DES Boom
Safety concerns and a retrenchment in usage have dimmed the luster of drug-eluting stents, but only slightly. If the market is to turn around and, more importantly, serve the kind of patients who really need these devices, a second-generation drug-eluting stent will be needed, one designed specifically for these new patients. And Xtent believe it has the technology to do just that.
Behind the DES Debate: A New Model for Device Development?
The drug-eluting stent is the rare cardiovascular device that has seen large companies dominate not just sales and distribution channels, but product development as well. But this big company dominance/small company exclusion in DES seems to be reversing itself, at least in part, if vibes from this year's PCR are to be trusted. Over the past half year or so, a series of newly released and much debated clinical studies, including BASKET-LATE and the Swedish DES registry SCAAR, have focused attention on DES safety issues, highlighting a small but meaningful risk of late-stent thrombosis, while the COURAGE trial has even pointed to efficacy concerns of percutaneous interventions, generally speaking. And that's opened the door to dozens of small and mid-sized companies that suddenly find themselves in the enviable position of seeing market and clinical pressures accelerating demand for quick development of their technologies.